Tuesday, February 11, 2020

OncoSec Gets Strategic Investment, Names New Board Members

San Diego-based OncoSec Medical, which is a public company developing late-stage intratumoral cancer immunotherapies, said it received a strategic investment from Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited, and its U.S. affiliate, Sirtex Medical US Holdings. As part of that investment, the company said it has named three new members of its board of directors, adding Yuhang Zhao of China Grand Enterprises, Chao Zhou of CGP and Kevin R. Smith of Sirtex. Zhao was previously Head of Global Strateg for Bayer Consumer Health, and also served at PaineWebber; Zhou is Executive Deputy Officer of China Grand Pharmaceutical and Healthcare Holdings Limited; and Smith is CEO of Sirtex Medical US Holdings.